

# Department of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

December 5, 2023: 6:00 – 8:30 p.m.

•	Executive Session	6:00 - 6:30
	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	6:30 - 6:35
	DVHA Pharmacy Administration Updates Gold Card Report	6:35 - 6:50
•	Chief Medical Officer Updates	6:50 - 6:55
•	<ul> <li>Follow-up Items from Previous Meetings</li> <li>Xeljanz® (tofacitinib) oral solution</li> <li>Kesimpta® (ofatumumab)</li> </ul>	6:55 – 7:00
	RetroDUR/ProDUR  Data presentation: "Triple Therapy": Opioids, Benzodiazepines, and Skeletal Muscle Relaxants	7:00- 7:25
	Clinical Update: Drug Reviews (Public comment prior to Board action)	7:25-7:45

### **Biosimilar Drug Reviews**

None at this time.

#### **Full New Drug Reviews**

(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)

- Abilify Asimtufii® (aripiprazole) and Uzedy® (risperidone)
- Inpefa® (sotagliflozin)
- Ligrev® (sildenafil)
- Konvomep® (omeprazole and sodium bicarbonate)
- Qalsody® (tofersen)
- Rebyota<sup>TM</sup> (fecal microbiota, live- jslm) and Vowst<sup>TM</sup> (fecal microbiota spores, live-brpk)
- Veozah<sup>TM</sup> (fezolinetant)
- Zavzpret<sup>TM</sup> (zavegepant)

#### New Managed Therapeutic Drug Classes

7:45 -7:55

Ophthalmic, Anti-VEGF and Miscellaneous Agents (new drug Syfovre® (pegcetacoplan) included)

(Public comment p	prior to Board a	ction
-------------------	------------------	-------

None at this time

•	Therapeutic Drug Classes – Periodic Review	7:55 - 8:30
	(Public comment prior to Board action)	

- Gastrointestinal Ulcer Therapies (new drug Konvomep® (omeprazole and sodium bicarbonate) included)
- H. Pylori Combination Treatments
- Hyperuricemia and Gout
- Ophthalmic, Allergic Conjunctivitis
- Ophthalmic, Antibiotics
- Ophthalmic, Anti-Inflammatories
- Ophthalmic, Dry Eye Treatments
- Ophthalmic, Glaucoma Agents
- Platelet Aggregation Inhibitors

# Review of Newly Developed/Revised Criteria (Public comment prior to Board action) 8:30 - 8:30

None at this time.

## ■ General Announcements 8:30 – 8:30

None at this time.

Adjourn 8:30